2023 World Conference on Lung Cancer (Posters)-P2.07. Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors

P2.07. Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate whether completing the full 35 cycles of pembrolizumab treatment is associated with further progression-free survival (PFS) outcomes in patients with non-small cell lung cancer (NSCLC) who have been durable progression-free survivors (dPFSors) for over 2 years. The study included data extracted from four clinical trials, with a total of 294 dPFSors. The patients were categorized based on whether they completed the full pembrolizumab treatment or not.<br /><br />The results showed that among the 294 patients, the overall PFS probability at 3 years was 44.9%. However, the patients who did not complete 35 cycles of pembrolizumab had inferior additional PFS compared to those who completed the full treatment (15.6 vs. 38.9 months, p < 0.001).<br /><br />Additionally, among the dPFSors who completed 35 cycles of pembrolizumab, the best response during the first course of treatment was associated with the additional 3-year PFS probability. Patients who had a complete response (CR) had a higher probability of PFS compared to those with a partial response (PR) or stable disease (SD), although this association was not statistically significant.<br /><br />The study concludes that not completing the full 35 cycles of pembrolizumab treatment may be associated with inferior long-term oncological outcomes in dPFSors. The findings highlight the need for further research in this population to better understand the impact of treatment duration on PFS outcomes.<br /><br />Overall, this study provides insights into the association between treatment duration and PFS outcomes in NSCLC patients who have been durable progression-free survivors.

Asset Subtitle

Lei Deng

Meta Tag

Speaker Lei Deng

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

pembrolizumab treatment

progression-free survival

non-small cell lung cancer

durable progression-free survivors

clinical trials

PFS probability

additional PFS

complete response

partial response

stable disease